The authors reply

New England Journal of Medicine

Volumn 368, Issue 9, 2013, Pages 873-

  Boonen, Steven ^a   Orwoll, Eric ^b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

AGE DISTRIBUTION; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HUMAN; INCIDENCE; LETTER; MORPHOMETRICS; OSTEOPOROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK REDUCTION; SPINE FRACTURE; MALE;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HUMANS; IMIDAZOLES; MALE; OSTEOPOROSIS; SPINAL FRACTURES;

EID: 84874351695     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1214992     Document Type: Letter

References (1)

1. Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:1799-809.